Therakind enters exclusive distribution partnership with Accord Healthcare
Geographic expansion as Jylamvo is launched in an additional three European countries
Geographic expansion as Jylamvo is launched in an additional three European countries
23 November 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with Accord Healthcare (“Accord”) for Therakind’s lead product, Jylamvo. The partnership also announces today the successful launch of Jylamvo in Poland and Romania.
Under this agreement, Accord secures exclusive rights to market, commercialise and sell Jylamvo in [Poland, Romania, and Czech Republic]. Jylamvo is already on sale in UK, Middle East, Greece and Portugal,
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“Therakind is committed to providing age-specific medicines designed to improve the lives of our patients. Jylamvo, our flagship product, is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. We are delighted to partner with Accord, whose commercial expertise and extensive reach in Europe will advance the commercial roll-out of Jylamvo. Our partnership has begun apace with Jylamvo already launched in an additional two countries and promises to be driving force for the growth of our brand reputation in Europe as momentum continues to build.”
James Burt, Executive Vice President, Accord Healthcare Europe added:
“Our track record of marketing over 700 products globally allows us to provide extensive commercial support for Therakind’s lead product. We are committed to bringing new complex, value-added products to improve the lives of the patients within our expansive portfolio and we look forward to a mutually beneficial, successful partnership with Therakind.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Therakind attends BIO Europe 2019
Therakind attends BIO Europe 2019
5 November 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, notes that CEO, Susan Conroy, will be attending BIO Europe 2019 in Hamburg, Germany on 11-13 November 2019 https://www.bio.org/events
BIO-Europe is a partnering conference for the life sciences industry that brings together international decision makers from the biotechnology, pharmaceutical and financial sectors. It offers networking opportunities, workshop and panel participation, high-profile exhibitions and prearranged one-to-one meetings.
Should you wish to set up a meeting during the conference, pleasecontact usor contact Dr Conroy through the BIO Convention website
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Therakind enters exclusive distribution partnership with Pharmapal
Access to Jylamvo continues to broaden access in Saudi Arabia, Kuwait, Jordan and Tunisia
Access to Jylamvo continues to broaden access in Saudi Arabia, Kuwait, Jordan and Tunisia
30 October 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with Pharmapal Drug Store LLC for Therakind’s lead product, Jylamvo.
Under this agreement, Pharmapal secures exclusive rights to market, commercialise and sell Jylamvo in Saudi Arabia, Kuwait, Jordan and Tunisia. Jylamvo is already on sale in UK, Greece, Poland and Romania.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“This partnership with Pharmapal further strengthens our reach across the UAE. Our focus is to provide age-specific medicines designed to account for impact of dosage in different age groups. Jylamvo is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. With Pharmapal’s expertise and network our vision is to improve patient care for all.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Pharmapal Drug Store LLC
Pharmapal Drug Store LLC was founded in 1998, as a full-service distributor handling exclusive products tailor-made to meet the demands of the middle east in its fast-growing landscape and continuous developments in the healthcare industry. Pharmapal distributes and sells in the middle east with its network of well-trained medical representatives and partnership with leading pharmaceutical and para-pharmaceutical groups ensuring the full coverage of the region. The company takes pride in its deeply rooted values to provide innovation & excellence in the service of better health to all.
Therakind attends BIO International 2019
Therakind attends BIO International 2019
28 May 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, notes that CEO, Susan Conroy, will be attending BIO International 2019 on 3-6 June 2019 in Philadelphia, USA. https://www.bio.org/events
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and in more than 30 other nations.
Should you wish to set up a meeting during the conference, pleasecontact usor contact Dr Conroy through the BIO Convention website.
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Blog Post Title One
It all begins with an idea.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
Don’t worry about sounding professional. Sound like you. There are over 1.5 billion websites out there, but your story is what’s going to separate this one from the rest. If you read the words back and don’t hear your own voice in your head, that’s a good sign you still have more work to do.
Be clear, be confident and don’t overthink it. The beauty of your story is that it’s going to continue to evolve and your site can evolve with it. Your goal should be to make it feel right for right now. Later will take care of itself. It always does.
Blog Post Title Two
It all begins with an idea.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
Don’t worry about sounding professional. Sound like you. There are over 1.5 billion websites out there, but your story is what’s going to separate this one from the rest. If you read the words back and don’t hear your own voice in your head, that’s a good sign you still have more work to do.
Be clear, be confident and don’t overthink it. The beauty of your story is that it’s going to continue to evolve and your site can evolve with it. Your goal should be to make it feel right for right now. Later will take care of itself. It always does.
Blog Post Title Three
It all begins with an idea.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
Don’t worry about sounding professional. Sound like you. There are over 1.5 billion websites out there, but your story is what’s going to separate this one from the rest. If you read the words back and don’t hear your own voice in your head, that’s a good sign you still have more work to do.
Be clear, be confident and don’t overthink it. The beauty of your story is that it’s going to continue to evolve and your site can evolve with it. Your goal should be to make it feel right for right now. Later will take care of itself. It always does.
Blog Post Title Four
It all begins with an idea.
It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.
Don’t worry about sounding professional. Sound like you. There are over 1.5 billion websites out there, but your story is what’s going to separate this one from the rest. If you read the words back and don’t hear your own voice in your head, that’s a good sign you still have more work to do.
Be clear, be confident and don’t overthink it. The beauty of your story is that it’s going to continue to evolve and your site can evolve with it. Your goal should be to make it feel right for right now. Later will take care of itself. It always does.
Therakind enters exclusive distribution partnership with Accord Healthcare
Geographic expansion as Jylamvo is launched in an additional three European countries
Geographic expansion as Jylamvo is launched in an additional three European countries
20 March 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive licensing and distribution agreement with Accord Healthcare (“Accord”) for Therakind’s lead product, Jylamvo. The partnership also announces today the successful launch of Jylamvo in Poland, Romania, and Czech Republic.
Under this agreement, Accord secures exclusive rights to market, commercialise and sell Jylamvo in Europe. Jylamvo is already on sale in UK, Middle East, Greece, Eastern Europe and Scandinavia.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and it use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Susan Conroy, CEO of Therakind, said:
“Therakind is committed to providing age-specific medicines designed to improve the lives of our patients. Jylamvo, our flagship product, is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. We are delighted to partner with Accord, who’s commercial expertise and extensive reach in Europe will advance the commercial roll-out of Jylamvo. Our partnership has begun apace with Jylamvo already launched in an additional three countries and promises to be driving force for the growth of our brand reputation in Europe as momentum continues to build.”
James Burt, Executive Vice President, Accord Healthcare Europe added:
“Our track record of marketing over 700 products globally allows us to provide extensive commercial support for Therakind’s lead product. We are committed to bringing new complex, value-added products to improve the lives of the patients within our expansive portfolio and we look forward to a mutually beneficial, successful partnership with Therakind.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche products in difficult-to-treat markets including paediatric and geriatric patient groups. We have three paediatric products on the market, with Jylamvo, our European approved oral methotrexate for treating rheumatological and dermatological diseases expanded to treat adults, and DriDose®, our Dry Powder Intranasal Device for the delivery of a dry powder drug formulation available for partnering. Our proprietary pipeline is focused on improving medicine adherence through easier dosing regimens and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
To find out more, please head to www.therakind.com
About Accord Healthcare
Headquartered in the United Kingdom (UK), Accord Healthcare Europe is one of the fastest growing pharmaceutical companies in Europe. Accord has one of the largest market footprints of any European generic and biosimilars companies selling generic medicines in over 80 countries around the world.
This global footprint enables us to deliver vital, affordable medicines to national health systems supporting healthcare professionals to transform patient lives worldwide.
Our approach is agile and inventive, always seeking to improve our products and patients’ access to them. We’re driven to think differently and deliver more for the benefit of patients worldwide.
Therakind enters exclusive distribution partnership with aVIPharma
Launch of Jylamvo in Greece
Launch of Jylamvo in Greece
28 February 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with a V.I. Pharma International S.A. (“aVIPharma ”) for Therakind’s lead product, Jylamvo.
Under this agreement, aVIPharma secures exclusive rights to market, commercialise and sell Jylamvo in Greece. Jylamvo is already available in the UK.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“Following the approval by the EMA in 2017, we are now focused on building out our distribution network to increase access to Jylamvo for our patients. aVIPharma has a strong market presence in Greece and we looking to building this partnership to provide age-specific medicines for all.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About a V.I. Pharma
A V.I. Pharma’s mission is to promote and deliver technologically advanced pharmaceutical products to patients who constitute “valuable rarities” need specific antidotes against the toxicity of the treatment received. its vision is to provide patients with access to standard technology-based therapies that serve personalized treatment and care.
Therakind enters exclusive distribution partnership with aVIPharma
Launch of Jylamvo in Greece
Launch of Jylamvo in Greece
28 February 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with a V.I. Pharma International S.A. (“aVIPharma ”) for Therakind’s lead product, Jylamvo.
Under this agreement, aVIPharma secures exclusive rights to market, commercialise and sell Jylamvo in Greece. Jylamvo is already available in the UK.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“Following the approval by the EMA in 2017, we are now focused on building out our distribution network to increase access to Jylamvo for our patients. aVIPharma has a strong market presence in Greece and we looking to building this partnership to provide age-specific medicines for all.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com